title: Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.
authors.forename: Fermin M
authors.initials: FM
authors.lastname: Sanchez-Guijo
authors.forename: Javier
authors.initials: J
authors.lastname: Lopez-Jimenez
authors.forename: Tomas
authors.initials: T
authors.lastname: Gonzalez
authors.forename: Carlos
authors.initials: C
authors.lastname: Santamaría
authors.forename: Marcos
authors.initials: M
authors.lastname: González
authors.forename: Maria-Consuelo
authors.initials: MC
authors.lastname: Del Cañizo
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D000069439:Dasatinib; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery*; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D003521:Cyclopropanes; D011720:Pyrazoles
chemical_list: D000970:Antineoplastic Agents; D000069439:Dasatinib; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; C484810:tozasertib; D003521:Cyclopropanes; D011720:Pyrazoles